Healthcare a Focus for Big Moves by Icahn
Legendary investor Carl Icahn, known for making headlines with big moves in the market, was increasing a handful of his major stakes during Q4.
Looking at Icahn’s top U.S.-listed, equity holdings at the end of 2009, Icahn was adding to stakes in pharmaceutical firms Genzyme (GENZ) and Forest Laboratories (FRX). Icahn was also upping his stake in video game maker Take-Two Interactive Software (TTWO).
Elsewhere, Icahn trimmed his stake in Yahoo (YHOO), where he sits on the board of directors.
Icahn also held steady with his investments in film company Lions Gate Entertainment (LGF), Motorola (MOT), railcar maker American Railcar Industries (ARII), and biotechs Amylin Pharmaceuticals (AMLN), Exelixis (EXEL) and Biogen Idec (BIIB), among others.
Looking at tickerspy.com’s graph charting the performance of Icahn’s end-of-2009 holdings so far in Q1, one can see that his top holdings have put in a very strong showing against the market of late. If you want to see the rest of Icahn’s top holdings, visit tickerspy.com to see his firm’s top positions and a chart of their combined performance.
Fun and informative, tickerspy.com is a free investing website where you can track multiple stock portfolios and compare against 250 proprietary Indexes tracking themes from dividends to ETFs to green energy to precious metals. Best of all, tickerspy.com lets you spy on the portfolios of nearly 3,000 Wall Street institutions and hedge funds and see graphs of their performance. Try tickerspy.com today and find out how you stack up against investing legends like Warren Buffett!
Pro portfolio performance is based on institutions’ top-15 holdings as disclosed in quarter-end filings with the SEC. Pro performance does not take into account additional holdings beyond the top 15 nor does it include positions that are not required to be disclosed by the SEC. As such, Pro portfolio performance should be considered an approximation and not a precise record of how an institution has performed over time.
More on this topic (What's this?)
(ELN) Elan Responds to Royalty Pharma Offer (Stock Blog Hub, 4/27/13)
(ACT) Actavis Beats on Earnings – Raises View (Stock Blog Hub, 5/14/13)
What To Expect When The Bureaucrats Take Over The Health Care System (The Cynical Economist, 3/28/13)
|Home | Find | Research | Track | Register | My Account | Logout||Web site design by LightMix|
|© 2010 Indie research Corp. All rights reserved.|